These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23537723)

  • 21. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
    Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
    Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
    Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
    Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma derivatives: new products and new approaches.
    Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
    Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
    Schulte S
    Thromb Res; 2008; 122 Suppl 4():S14-9. PubMed ID: 18929521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
    Santagostino E; Martinowitz U; Lissitchkov T; Pan-Petesch B; Hanabusa H; Oldenburg J; Boggio L; Negrier C; Pabinger I; von Depka Prondzinski M; Altisent C; Castaman G; Yamamoto K; Álvarez-Roman MT; Voigt C; Blackman N; Jacobs I;
    Blood; 2016 Apr; 127(14):1761-9. PubMed ID: 26755710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
    Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
    Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion
    Lyseng-Williamson KA
    Drugs; 2017 Jan; 77(1):97-106. PubMed ID: 27988873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW; Montgomery RR; Pratt KP; Lenting PJ; Lillicrap D
    Blood; 2016 Oct; 128(16):2007-2016. PubMed ID: 27587878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 39. Innovations in coagulation: improved options for treatment of hemophilia A and B.
    Pabinger-Fasching I; Pipe S
    Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances in surgery and its perioperative treatment in people with hemophilia.
    Rodríguez-Merchán EC
    Expert Rev Hematol; 2021 Mar; 14(3):271-280. PubMed ID: 33605827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.